Nanjing Delova Biotech Co., Ltd.

Established in 2017 and based in Nanjing, China, Nanjing Delova Biotech Co. , Ltd. is a biotechnology pharmaceutical company that focuses on the development of new drugs in the field of pain management. It has established an R&D center in Nanjing and a subsidiary in California.

The company has nearly 60 employees, with a master’s and Ph. D. degrees account for nearly 60%. Mr.

Qingsong Wang, the founder and CEO of the company, graduated from China Pharmaceutical University. The co-founder and CSO of the company, Mr. Ning Hu graduated from the University of Southern California. In June 2025, Nanjing Delova Biotech Co.

, Ltd. closed a venture funding round from new investor Yikai Ventures, returning investors Hyfinity Investments Legend Capital and Zhongqi Capital also joined the round. The company focuses on the research and development of drugs in the field of pain management, and it has laid out nearly 10 non-opioid analgesics. It has developed several independent intellectual property technology products such as extended and controlled release injection, topical transdermal technology and solubility enhancement technology for insoluble drugs, which covers postoperative pain, aesthetic surgery pain, multiple neuropathic pains, osteoarthritis pain, migraine and trigeminal neuralgia.

Nanjing Delova Biotech Co. , Ltd. also focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, prodrug modification, etc. The company’s revenue is generated by the development and eventual commercialization of its proprietary drug formulations.